Facheris, G.; Cossali, G.; Imbrescia, J.; La Mattina, S.; Mataj, E.; Meli, N.; Volpi, G.; Triggiani, L.; Guerini, A.E.; Levi, G.;
et al. Real-World Insights into the Impact of Durvalumab on Stage III Unresectable Non-Small Cell Lung Cancer—A Narrative Review. Cancers 2025, 17, 874.
https://doi.org/10.3390/cancers17050874
AMA Style
Facheris G, Cossali G, Imbrescia J, La Mattina S, Mataj E, Meli N, Volpi G, Triggiani L, Guerini AE, Levi G,
et al. Real-World Insights into the Impact of Durvalumab on Stage III Unresectable Non-Small Cell Lung Cancer—A Narrative Review. Cancers. 2025; 17(5):874.
https://doi.org/10.3390/cancers17050874
Chicago/Turabian Style
Facheris, Giorgio, Gianluca Cossali, Jessica Imbrescia, Salvatore La Mattina, Eneida Mataj, Nicole Meli, Giulia Volpi, Luca Triggiani, Andrea Emanuele Guerini, Guido Levi,
and et al. 2025. "Real-World Insights into the Impact of Durvalumab on Stage III Unresectable Non-Small Cell Lung Cancer—A Narrative Review" Cancers 17, no. 5: 874.
https://doi.org/10.3390/cancers17050874
APA Style
Facheris, G., Cossali, G., Imbrescia, J., La Mattina, S., Mataj, E., Meli, N., Volpi, G., Triggiani, L., Guerini, A. E., Levi, G., Grisanti, S., Buglione di Monale e Bastia, M., & Borghetti, P.
(2025). Real-World Insights into the Impact of Durvalumab on Stage III Unresectable Non-Small Cell Lung Cancer—A Narrative Review. Cancers, 17(5), 874.
https://doi.org/10.3390/cancers17050874
